Debt-to-equity of Blueprint Medicines Corp from 30 Jun 2019 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Blueprint Medicines Corp quarterly Debt-to-equity in % history and change rate from 30 Jun 2019 to 31 Mar 2025.
  • Blueprint Medicines Corp Debt-to-equity for the quarter ending 31 Mar 2025 was 275%, a 21% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Blueprint Medicines Corp Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 275% -75% -21% 31 Mar 2025
Q4 2024 272% -51% -16% 31 Dec 2024
Q3 2024 318% +86% +37% 30 Sep 2024
Q2 2024 356% +183% +106% 30 Jun 2024
Q1 2024 350% +225% +179% 31 Mar 2024
Q4 2023 323% +239% +282% 31 Dec 2023
Q3 2023 231% +176% +315% 30 Sep 2023
Q2 2023 173% +141% +447% 30 Jun 2023
Q1 2023 125% +102% +448% 31 Mar 2023
Q4 2022 85% +65% +329% 31 Dec 2022
Q3 2022 56% +38% +222% 30 Sep 2022
Q2 2022 32% +14% +84% 30 Jun 2022
Q1 2022 23% +3% +15% 31 Mar 2022
Q4 2021 20% -3.8% -16% 31 Dec 2021
Q3 2021 17% -14% -44% 30 Sep 2021
Q2 2021 17% -24% -58% 30 Jun 2021
Q1 2021 20% -20% -51% 31 Mar 2021
Q4 2020 24% -22% -49% 31 Dec 2020
Q3 2020 31% -9.4% -23% 30 Sep 2020
Q2 2020 42% +6.1% +17% 30 Jun 2020
Q1 2020 40% 31 Mar 2020
Q4 2019 46% 31 Dec 2019
Q3 2019 40% 30 Sep 2019
Q2 2019 35% 30 Jun 2019
* An asterisk sign (*) next to the value indicates that the value is likely invalid.